Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlpha Tau Medical Ltd

Alpha Tau Medical Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
13.72 USD 0.42 ( 3.16%)
Last update at 2026-11-06T21:00:00Z
VOLUME
417275
Market Cap
695.28M

Momentum Score

…

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.16
Low
13.98
High
52 Week Price Range
2.50
Low
8.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alpha Tau Medical Ltd develops targeted alpha therapies that attach the alpha-emitter thorium-227 to tumor-targeting molecules for oncology indications. Long-term growth could be supported by clinical trial progress, potential regulatory approvals, broader adoption of targeted radiopharmaceuticals and commercial partnerships. The platform may benefit from the high potency and short tissue range of alpha emitters and exposure to multiple cancer indications.
Material risks include clinical and regulatory failure, manufacturing and supply-chain complexity for radioisotopes, substantial ongoing financing needs and competition from established radioligand and oncology players.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
13.30
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.18
ROE
-61.00%
Net Debt
-2.25M
ROCE
-44.02%
Diluted EPS TTM
-0.52

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -42.51M -31.74M -29.14M -33.74M -27.26M
Minority interest - - - - 0.00M
Net income -42.63M -31.75M -29.16M -33.76M -27.27M
Selling general administrative 8.36M 6.67M 7.33M 10.27M 1.86M
Selling and marketing expenses 1.86M 1.25M 1.92M 0.97M 0.48M
Gross profit -1.23M -1.10M -1.07M - -
Reconciled depreciation 1.23M 1.10M 1.07M 0.98M 0.78M
Ebit -42.29M -31.40M -29.10M -33.12M -14.57M
Ebitda -41.06M -30.30M -28.03M -32.14M -13.79M
Depreciation and amortization 1.23M 1.10M 1.07M 0.98M 0.78M
Operating income -42.29M -36.04M 35.68M -32.14M -13.79M
Other operating expenses 42.29M 36.04M 35.68M 32.14M 13.79M
Interest expense 0.42M 0.34M 0.04M 1.77M 12.70M
Tax provision 0.12M 0.01M 0.02M 0.02M 0.01M
Interest income 3.84M 4.28M 4.83M 1.79M 0.21M
Net interest income 3.42M 3.93M 4.72M 1.77M 0.20M
Income tax expense 0.12M 0.01M 0.02M 0.02M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 41.06M 34.94M 34.61M 32.14M 13.79M
Cost of revenue 1.23M 1.10M 1.07M - -
Total other income expense net -0.22M 4.30M 6.54M -1.61M -13.47M
Net income from continuing ops -42.63M -31.75M -29.16M -33.76M -27.27M
Net income applicable to common shares - - - -33.76M -27.27M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 106.58M 86.20M 107.39M 120.15M 42.22M
Other current assets 1.36M 4.30M 0.80M 1.92M 1.30M
Total liab 29.48M 23.54M 22.91M 14.49M 76.99M
Total stockholder equity 77.10M 62.67M 84.47M 105.66M -34.78M
Other current liab 5.51M 3.12M 3.47M 2.25M 3.20M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -190.14M -147.51M -115.76M -86.60M -52.84M
Other liab - - - 5.63M -
Other assets - - - 0.39M 2.03M
Cash 15.98M 13.72M 15.81M 5.84M 23.24M
Total current liabilities 10.51M 8.68M 7.10M 4.34M 4.41M
Net debt -2.25M -1.19M -2.53M -0.64M -23.24M
Short term debt 1.13M 2.02M 1.06M 0.67M -
Short long term debt total 13.73M 12.54M 13.28M 5.19M -
Other stockholder equity 267.24M 210.18M 200.23M 192.26M 18.06M
Property plant equipment - - - 13.28M 7.55M
Total current assets 78.30M 64.23M 85.76M 106.48M 32.64M
Net tangible assets - - - 105.66M -34.78M
Short term investments 60.92M 45.88M 69.13M 98.69M 8.08M
Net receivables 0.04M 0.33M 0.02M 1.10M 0.71M
Long term debt 6.35M 5.56M 5.61M - -
Inventory - - - -1.06M -
Accounts payable 3.87M 3.53M 2.57M 1.42M 1.20M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.48M 0.43M 0.47M 0.39M 2.03M
Non current assets total 28.28M 21.98M 21.63M 13.67M 9.57M
Capital lease obligations 7.37M 6.97M 7.67M 5.19M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -14.51M 20.77M 18.68M -89.94M 22.20M
Change to liabilities - - - 0.22M 0.24M
Total cashflows from investing activities -20.59M 20.77M 18.68M -89.94M 19.27M
Net borrowings 0.00M 0.00M 5.25M - -
Total cash from financing activities 45.77M 0.03M 5.30M 96.91M 0.11M
Change to operating activities - - - -0.53M 0.35M
Net income -42.63M -31.75M -29.16M -33.76M -27.27M
Change in cash -1.00M 1.17M 9.12M -17.17M 7.68M
Begin period cash flow 16.98M 15.81M 6.69M 23.85M 16.17M
End period cash flow 15.98M 16.98M 15.81M 6.69M 23.85M
Total cash from operating activities -26.68M -19.78M -17.96M -23.88M -11.81M
Issuance of capital stock 45.50M 0.00M 0.00M 0.00M 0.00M
Depreciation 1.23M 1.10M 1.07M 0.98M 0.78M
Other cashflows from investing activities - -0.10M 25.08M - -
Other cashflows from financing activities - 0.03M 5.25M 96.91M 19.27M
Change to netincome - - - 9.21M 14.10M
Capital expenditures 6.08M 2.24M 6.40M 0.90M 2.93M
Change in working capital 2.29M 1.17M 2.49M -0.31M 0.58M
Stock based compensation 10.62M 9.92M 7.93M 6.75M 0.81M
Other non cash items 12.42M -0.22M -0.29M 2.46M 0.03M
Free cash flow -32.76M -22.02M -24.36M -24.78M -14.74M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
DRTS
Alpha Tau Medical Ltd		 0.42
3.16%		 13.72 - - - 9.25 -4.77
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Alpha Tau Medical Ltd

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Kiryat HaMada St. 5, Jerusalem, Israel, 9777605

972 3 577 4115

https://www.alphatau.com

121

Name Title Year Born
Mr. Uzi Sofer CEO & Chairman 1970
Mr. Raphi Levy Chief Financial Officer 1985
Mr. Amnon Gat Chief Operations Officer 1975
Mr. Ronen Segal Chief Technology Officer 1973
Prof. Yona Keisari Chief Scientific Officer & Member of Scientific Advisory board 1947
Ms. Rebecca Becker VP of legal NA
Mr. Peter M. Melnyk Chief Commercial Officer 1962
Dr. Robert B. Den M.D. Chief Medical Officer & Member of Scientific Advisory Board 1979
Prof. Itzhak Kelson Chief Physics Officer & Member of Scientific Advisory Board 1940
Ms. Yael Zeiger Corp. Controller 1983

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…